Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer
Our study highlights the critical need for blocking both intrinsic and extrinsic mechanisms of resistance for the prolonged response and shows that such treatment is ineffective in KRAS<sup>G12C</sup>i-AcR tumors.
Authors
- Sooraj Mathukkada (ORCID: https://orcid.org/0000-0002-0210-2399)
- Manu Prasad (ORCID: https://orcid.org/0000-0001-7690-3511)
- Dexin Kong (ORCID: https://orcid.org/0000-0002-8064-1435)
- Baisali Bhattacharya (ORCID: https://orcid.org/0000-0003-3399-7399)
- Sankar Jagadeeshan (ORCID: https://orcid.org/0000-0002-3778-8757)
- Talal Ben Lulu (ORCID: https://orcid.org/0000-0001-5337-9497)
- Moshe Elkabets (ORCID: https://orcid.org/0000-0003-3634-9098)
- Angel Porgador (ORCID: https://orcid.org/0000-0003-1540-4449)
- Ofra Novoplansky (ORCID: https://orcid.org/0000-0002-1239-7856)
- Yariv Greenshpan
- Ksenia M. Yegodayev (ORCID: https://orcid.org/0000-0003-0721-838X)
- Johannes Brägelmann (ORCID: https://orcid.org/0000-0002-1306-2169)
- Raghda Abu Shareb
- Divyasree Marripati
- J. Silvio Gutkind
Institutions
- Ben-Gurion University of the Negev (IL)
- University of Cologne (DE)
- University of California San Diego (US)
- University Hospital Cologne (DE)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2024-11-20
- DOI
- https://doi.org/10.1186/s13046-024-03227-0
- Citations
- 6
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 1.70
Funders
- United States - Israel Binational Science Foundation
- Deutsches Krebsforschungszentrum
- National Natural Science Foundation of China
- Israel Science Foundation
- Ben-Gurion University of the Negev